Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation

Trial Profile

Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Fludarabine (Primary) ; Melphalan (Primary)
  • Indications Haematological malignancies; Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Oct 2017 Planned initiation date changed from 1 Jul 2017 to 1 Dec 2017.
    • 24 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top